BMC Endocrine Disorders (Jun 2022)

A case of familial hypocalciuric hypercalcemia type 1 due to CASR p.Pro55Leu mutation

  • Akira Sumida,
  • Katsumi Iizuka,
  • Takehiro Kato,
  • Yanyan Liu,
  • Sodai Kubota,
  • Saki Kubota-Okamoto,
  • Teruaki Sakurai,
  • Toshinori Imaizumi,
  • Yoshihiro Takahashi,
  • Masami Mizuno,
  • Ken Takao,
  • Takuo Hirota,
  • Tetsuya Suwa,
  • Yukio Horikawa,
  • Mayumi Yamamoto,
  • Yusuke Seino,
  • Atsushi Suzuki,
  • Daisuke Yabe

DOI
https://doi.org/10.1186/s12902-022-01077-5
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Background Familial hypocalciuric hypercalcemia (FHH) is a rare autosomal dominant disease, which requires differential diagnosis from relatively common primary hyperparathyroidism (PHPT) in order to avoid unnecessary surgery. Case presentation A 16-year-old female had been followed by the department of psychosomatic medicine at our institution. Throughout the follow-up period, her plasma calcium levels were high, plasma Pi levels were relatively low, and plasma intact PTH was relatively high. She was referred to our department to determine the cause of her hypercalcemia. Her 24 h urinary calcium excretion was as low as 100 mg/day, and calcium creatinine clearance ratio was below 0.01. Moreover, she had a family history of hypercalcemia (proband, her brother, and her father). The genetic testing for her family revealed that she, her brother, and her father were definitively diagnosed with FHH type 1 due to the heterozygous calcium-sensing receptor mutation (NM_00388:4:c.164C > T:p.Pro55Leu). Conclusion We experienced a 16-year-old female with FHH, in whom genetic testing identified the heterozygous calcium-sensing receptor mutation (NM_00388:4:c.164C > T:p.Pro55Leu) as pathogenic, permitting a definitive diagnosis of FHH type 1. The genetic testing for calcium sensing receptor is beneficial to distinguish asymptomatic primary hyperparathyroidism from FHH.

Keywords